Canadian Organization for Rare Disorders

What Canadian Organization for Rare Disorders does

The Canadian Organization for Rare Disorders (CORD) is a Canadian non-profit charitable organization founded in 1990 and headquartered in Toronto (212 King St. W., Suite 600). It serves as the national network representing patient organizations for rare disorders across Canada, with an estimated 3.5 million Canadians (approximately 1 in 12) affected by rare disorders and a core constituency of patient groups, caregivers, and families. The organization operates as a volunteer-based entity with 1-10 staff under the leadership of President & CEO Durhane Wong-Rieger, who also chairs Rare Diseases International. CORD is registered as a charity under Registration No. 89651 3355 RR0001.

CORD's core activities are advocacy coordination, awareness campaigns, educational conferences, and policy engagement. Its product offerings include membership programs (individual, affiliate patient groups, and corporate pharmaceutical tiers), the annual Rare Disease Day campaign (with Canadian landmark illuminations including CN Tower and Niagara Falls), the Fight for Our Lives multi-year funding campaign, the Patient d'exception campaign in Quebec, and educational resources/publications. The organization does not develop or sell software products; its primary platform is the raredisorders.ca website used for member communication, event promotion, and information distribution. Notable strategic outputs include contributing to the federal $1.4 billion National Strategy for Drugs for Rare Diseases (2024-25 to 2026-27), under which nine rare disease drugs have been funded at the strategy's midpoint, and a partnership with Ipsos to conduct a national survey on the impact of living with rare disease in Canada.

CORD's business model relies on a hybrid of charitable donations and tiered membership subscriptions. Revenue streams include individual donations, individual/affiliate membership fees, and corporate pharmaceutical membership fees from 22 companies including Alexion, Novartis, Pfizer, Roche, Sanofi, Biogen, BioMarin, Amgen, and others. The organization operates exclusively within Canada while maintaining international ties through Rare Diseases International, and its customer concentration spans individual patients, patient organizations, and corporate pharmaceutical members.

Name

Canadian Organization for Rare Disorders

Legal name

Canadian Organization for Rare Disorders

Website

https://raredisorders.ca

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1–10 employees

Short description

CORD is a Canadian non-profit founded in 1990 serving as the national network for patient organizations representing Canadians affected by rare disorders, providing advocacy, awareness campaigns, and policy engagement for approximately 3.5 million affected individuals.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations: CORD accepts donations to fund advocacy, education, and research programs for rare disorders. The organization describes itself as a volunteer-based organization relying on financial contributions to support its mission.
2. Membership Fees: CORD operates with individual, affiliate, and corporate membership categories. Corporate members include pharmaceutical companies such as Alexion, Novartis, Pfizer, Roche, and others. Membership fees support the organization's operations and advocacy work.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

CORD is Canada's national network of organizations representing individuals and families affected by rare disorders. It delivers advocacy coordination, awareness campaigns (e.g., Rare Disease Day, Fight for Our Lives), educational resources, and policy development aimed at improving diagnosis, treatment access, and care for the rare disease community in Canada. The organization is funded through individual donations, membership fees, and corporate pharmaceutical sponsorships.

Product overview

The Canadian Organization for Rare Disorders (CORD) is a non-profit advocacy organization, not a technology product company. It operates as Canada's national network for rare disease patient organizations, providing advocacy services, educational resources, awareness campaigns, and membership programs. CORD does not develop or sell software products; instead, it offers advocacy coordination, policy development, awareness campaigns (including Rare Disease Day, Fight for Our Lives, and Patient d'exception), educational events and conferences, and membership services for patient groups and industry partners. The organization focuses on health policy advocacy to improve access to treatments, diagnostics, and care for Canadians affected by rare disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• CORD Membership Program Tiered membership offering providing individuals, affiliate patient organizations, and corporate pharmaceutical sponsors with access to CORD's national advocacy network, awareness campaigns, educational resources, and policy engagement opportunities in the rare disease community.
• Rare Disease Day Campaign Annual awareness campaign coordinated by CORD to raise public and policy-maker awareness of rare disorders and the challenges faced by the rare disease community in Canada.
• Patient d'exception Campaign Campaign coordinated by CORD that highlights exceptional individual patient stories from the rare disease community to raise awareness and humanize the policy case for improved rare disease care.
• Fight for Our Lives Campaign Advocacy campaign coordinated by CORD aimed at improving access to diagnosis, treatment, and care for the rare disease community in Canada.
• Educational Resources and Publications Educational resources and publications produced by CORD to inform the rare disease community, patient organizations, and policy-makers about rare disorder issues, treatments, and policy developments in Canada.

Quantifiable outcome

• Federal government commitment of $1.4 billion for rare disease drugs over three years through National Strategy
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• IpsoscoreStrategic or Co-development Partner · 1 March 2023CORD is collaborating with Ipsos to conduct a national survey of Canadian families measuring the impact of living with a rare disease. This survey builds on similar studies from Europe, Japan, and the United States. Canadian results are intended to guide federal and provincial system reforms for rare diseases.
• Corporate Pharmaceutical MemberscoreGTM or Marketing Partner22 pharmaceutical companies serve as corporate members including Alexion, Novartis, Pfizer, Roche, Sanofi, and others. These partnerships support CORD's operations and provide industry perspective on rare disease drug access and policy discussions.
• Regroupement québécois des maladies orphelines (RQMO)coreStrategic or Co-development PartnerCollaboration with Quebec's rare disease organization (RQMO) for the 2024 Fall Conference held in Montreal. Represents regional partnership for rare disease advocacy in Quebec.
• Health CanadacoreStrategic or Co-development PartnerCORD works with Health Canada on the National Strategy for Drugs for Rare Diseases, providing patient community input on drug reimbursement, screening, diagnosis, and rare disease care programs.
• Canada's Drug Agency (CDA)coreStrategic or Co-development PartnerEngagement with CDA on health technology reviews for rare disease drugs. CORD advocates for patient perspectives in drug assessment processes and reimbursement decisions.
• Provincial and Territorial GovernmentscoreStrategic or Co-development PartnerCORD advocates for implementation of rare disease strategies at provincial and territorial levels through bilateral funding agreements under the $1.4 billion federal National Strategy.
• Rare Diseases InternationalmajorStrategic or Co-development PartnerCORD CEO Durhane Wong-Rieger serves as chair of Rare Diseases International, connecting Canadian rare disease advocacy to global initiatives and international best practices.
• BC Ministry of HealthminorOthersEngagement on individual patient cases such as advocacy for continued access to Brineura for CLN2 patient Charleigh Pollock. Represents patient advocacy in provincial drug funding decisions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Best Medicines Coalition: Canadian alliance of patient organizations focused on drug access, reimbursement, and health technology assessment processes. Direct peer in Canadian patient-advocacy-on-drug-access space, working alongside CDA and Health Canada on reimbursement.
• National Organization for Rare Disorders (NORD): US national rare disease patient advocacy alliance. Direct comparable peer: membership-based organization representing patient groups, advocating for rare disease policy and drug access, with corporate pharma members and a national awareness day.
• EURORDIS - Rare Diseases Europe: European non-profit alliance of rare disease patient organizations. Direct peer in mission (unified advocacy voice for rare disease patients) and in operating model (membership-based, policy-focused, working with regulators and industry across multiple countries).
• Health Charities Coalition of Canada: Coalition of national health charities in Canada. Peer in operating model (membership-based umbrella of patient/disease organizations doing policy advocacy in Ottawa) and overlapping government and pharma relationships.
• Regroupement québécois des maladies orphelines (RQMO): Quebec-based rare disease patient organization that co-hosts CORD's Montreal conference. Direct Canadian peer operating the same advocacy, awareness, and policy engagement model at a sub-national level.

Emerging players

• Genetic Alliance: US-based umbrella organization for genetic and rare disease advocacy groups. Peer in mission (supporting and convening patient organizations in the rare/genetic disease space) and in policy and research engagement, though US-focused.
• Cystic Fibrosis Canada: Canadian disease-specific patient advocacy and research charity. Peer in Canadian rare/genetic disease advocacy model, government relations, and pharma partnerships, though focused on a single condition rather than umbrella rare disorders.
• ALS Society of Canada: Canadian disease-specific advocacy organization. Peer in Canadian patient-advocacy charity model, federal-provincial drug access advocacy, and pharma partnerships, though with a narrower disease focus.

Regional players

• Rare Voices Australia: Australia's national rare disease patient advocacy alliance. Strong functional peer (similar national alliance model, awareness campaigns, government engagement) but operating in a different geography.

Broad incumbents

• Canadian Organization for Cancer Survivorship / Canadian Cancer Society: Large established Canadian health charity. Peer in non-profit patient-advocacy model, federal policy engagement, and corporate pharma membership structure, but at significantly greater scale and broader disease mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/canadian-organization-for-rare-disorders
• Xx.com/raredisorders
• Facebookfacebook.com/RareDisorders

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canadian Organization for Rare Disorders